Evidence map›Paper›PMID 39673675›Full record

ArticleImmunologic research2024

Prognostic value of myeloid-derived suppressor-like cells in acute myeloid leukemia: insights from immunophenotyping and clinical correlations.

Alexia N Sant'Ana, Camila K Dias, Vitória B S Nunes, Mariela G Farias, Ana P Alegretti, Pâmela Portela, Ebellins T Calvache, Maria F Meirelles, Liane E Daudt, Mariana B Michalowski and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alexia N Sant'AnaLaboratório de Imunobioquímica do Câncer, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, 90035-003, Brazil.
Camila K DiasLaboratório de Imunobioquímica do Câncer, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, 90035-003, Brazil.
Vitória B S NunesLaboratório de Imunobioquímica do Câncer, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, 90035-003, Brazil.
Mariela G FariasUnidade de Hematologia e Citometria de Fluxo, Serviço de Diagnóstico Laboratorial, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil.
Ana P AlegrettiSetor de Inovação, Serviço de Diagnóstico Laboratorial, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil.
Pâmela PortelaUnidade de Hematologia e Citometria de Fluxo, Serviço de Diagnóstico Laboratorial, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil.
Ebellins T CalvacheServiço de Hematologia Clínica, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil.
Maria F MeirellesServiço de Hematologia Clínica, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil.
Liane E DaudtServiço de Hematologia Clínica, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil.
Mariana B MichalowskiPrograma de Pós-Gradução em Saúde da Criança e do Adolescente, UFRGS, Porto Alegre, RS, 90035-003, Brazil.
Alessandra A PazServiço de Hematologia Clínica, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil.
Fabrício FigueiróLaboratório de Imunobioquímica do Câncer, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, 90035-003, Brazil. fabricio.figueiro@ufrgs.br.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico CNPq n°406035/2021-0Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul FAPERGS/PQG Grant nº 21/2551-0001972-7Fundo de Incentivo à Pesquisa - Hospital de Clínicas de Porto Alegre FIPE/HCPA project nº 2021-0512Instituto Nacional de Ciência e Tecnologia INCT/CNPq/CAPES/FAPERGS Grant nº 465671/2014-4
6 · The paper itself

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population that acts on both innate and adaptive immunity, fostering immune escape in tumors and contributing to cancer progression. Despite the lack of definitive markers for immunophenotyping MDSCs, particularly the polymorphonuclear (PMN-MDSC) subset, these cells seem to play a crucial role in acute myeloid leukemia (AML) patients' prognosis. Additionally, the maturation stage of MDSCs remains a subject of debate and is largely unknown within the AML context. In this study, we conducted a retrospective analysis of flow cytometry immunophenotyping data obtained at the diagnosis of AML patients. We explored how the enrichment of neutrophil maturation stages, the frequency of PMN-MDSC-like cells and monocytic MDSC-like population (M-MDSC-like), and the ratios of MDSC-like cells to T lymphocytes correlate with relevant prognostic indicators. Our findings revealed that CD45

Indexed as

ImmunophenotypingLeukemia, Myeloid, AcuteMyeloid-Derived Suppressor CellsAdultAgedAged, 80 and overAntigens, CDFemaleFlow Cytometryfms-Like Tyrosine Kinase 3HumansMaleMiddle AgedMutationNeutrophilsPrognosisAntigens, CDfms-Like Tyrosine Kinase 3Acute myeloid leukemiaM-MDSCsNeutrophil maturation stagesPMN-MDSCsPrognosis

Identifiers

PMID39673675

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.